secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001193125-22-279068
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines reports Q3 net loss $73.3M; cash $655M; clinical trials progressing
--------------------------------------------------------------------------------

- Net loss of $73.3M for Q3 2022, up from $52.9M in Q3 2021; revenue $3.4M from Sanofi collaboration.
- Cash, equivalents, and marketable securities $655M as of Sep 30, 2022, boosted by July 2022 equity offering of $264.5M gross.
- Phase 1/1b trials ongoing for RMC-6236 (RAS MULTI) and RMC-6291 (KRAS G12C); first data expected in 2023.
- RMC-9805 (KRAS G12D) first patient dosing expected mid-2023.
- Full-year 2022 GAAP net loss guidance reiterated at $260M-$280M; cash runway through 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522279068/0001193125-22-279068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312522279068/d418464d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-279068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer